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Figure 1   Multiple oral ulcers.
One year prior to admission, the patient had 
multiple ulcers on his genitalia. The lesions were 
located in the glans and ventral part of penis, 
scrotum, and inguinal (fi gure 2). There was no 
history of multiple sex partners or previous sexually 
transmitted disease. He was subsequently referred 
to the Department of Dermato-Venereology.
Figure 2   Genital ulcers: (A) scrotum and inguinal; 
(B) scrotum; (C) glans penis; (D) ventral part of penis.
At the same time, the patient also complained 
of having skin lesions in the form of red acne-like 
papules. These lesions were found on his chest 
(anterior and posterior), face, and neck (fi gure 3). 
The dermatologist performed some laboratory 
investigation and administer topical ointment and 
methylprednisolone 24 mg a day for a week. After a 
few months of therapy, the skin and genital lesions 
disappeared, but the oral lesions persisted.
Figure 3   Acneiform lesions on chest and face.
Behçet’s disease (BD) is a chronic, relapsing, 
infl ammatory disease characterized by recurrent oral 
aphthae and any of several systemic manifestations 
that include genital aphthae, ocular disease, skin 
lesions, neurologic disease, vascular disease, or 
arthritis. Hippocrates may had described BD in 
the fi fth century B.C.; however, the fi rst offi cial 
description of the syndrome was attributed to the 
Turkish dermatologist Hulusi Behçet in 1924. In 
1930, the Greek physician Adamantiades reported 
a patient with infl ammatory arthritis, oral and 
genital ulcers, phlebitis, and iritis.1 Since then, the 
syndrome has been referred to as BD.1,2
 The manifestations of BD are thought to be 
caused by an underlying vasculitis. Although this 
disease is recognized worldwide, the prevalence 
is highest in the eastern Mediterranean, the 
Middle Eastern, and East Asian countries, thus the 
nickname Silk Road disease. The disease tends to 
be more severe in areas where it is more common. 
Prevalence rates all over the world are increasing, 
probably because of improved recognition and 
reporting. Behçet’s disease occurs primarily in 
young adults. The mean age at onset is between 
25 and 30 years. The incidence of disease in males 
and females is approximately equal along the Silk 
Road, but in Japan, Korea, and Western countries 
the disease occurs more frequently in women. Case 
confi rmation can be challenging because many 
patients labeled as having BD have oral ulcers as 
the primary or sole manifestation.3
CASE REPORT
A 35-year-old man was referred to the Division 
of Rheumatology by the Department of Dermato-
Venereology with chief complaint of having pain 
in his ankle for 3 days. The pain had worsen with 
activity and caused diffi culty in walking or moving 
the ankle. There was no fever, swelling, or any 
history of trauma. During physical examination, 
we found tenderness of achilles tendon without any 
other sign of infl ammation. There was also history 
of pain and stiffness in his shoulder and knee 2 
weeks prior, but those symptoms had disappeared 
without treatment.
Five years prior to admission, the patient started 
to develop painful and irritating multiple oral ulcers. 
This symptom persisted despite treatments given 
by general practitioners and dentist, and continued 
for years without improvement (fi gure 1).
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Two weeks prior to admission, the patient complained of 
blurred vision of his right eye. There was history of redness, 
but there was neither pain nor discharge from the eye. The 
Department of Ophthalmology then confi rmed that the patient 
had panuveitis of the right eye.
Routine laboratory investigation only revealed leukocytosis 
(14.55 × 103/mm3). The X-ray of the pelvis and foot were 
normal. The investigation of C-reactive protein was 51 mg/
L, antinuclear antibodies was positive with titer of 1/100 and 
a speckled pattern, anti–double-stranded DNA was negative, 
and complement component (C)3 and C4 were within normal 
limit. We also performed the examination of antibody for 
some viruses and parasites infection like herpes simplex virus 
(HSV), cytomegalovirus (CMV), and Treponema pallidum. 
We found positivity of IgM of HSV II and IgG of anti-CMV. 
The rapid test for human immunodefi ciency virus of this 
patient was negative.
We gave the patient high dose of steroid at the beginning 
of therapy: methylprednysolone at 1 mg/kg bodyweight for 
2 weeks and then tapered it down. The patient also received 
topical corticosteroid as the treatment for his eye. After 2 
weeks of treatment, the symptoms of blurred vision did not 
show any improvement, but the arthralgia had diminished. 
An additional treatment with acyclovir for 1 week were also 
administered, but with no effect on his symptoms. We then 
made the decision to give the patient azathioprine with a dose 
of 50 mg to 150 mg. His symptoms improved, and he reported 
80% recovery of his vision. The patient was then confi rmed to 
have attained remission from the disease.
DISCUSSION
The common clinical feature in patients with BD is the 
presence of recurrent and usually painful mucocutaneous 
ulcers.4 Aphthous oral ulcers is usually the fi rst and most 
persistent clinical feature of BD. Lesions occur in crops and 
some patients may have them during most of the course of the 
disease. Aphthae occur as ulcers that are 2 to 12 mm or larger. 
These are discrete, painful, round or oval red-rimmed lesions 
that affect mainly the nonkeratinized mucosa of the cheeks, 
the border of the tongue, the soft palate, and the pharynx. 
Genital ulcers resemble oral aphthae but occur less frequently. 
They occur as single or multiple lesions of the vulva and in the 
vagina, or on the scrotum or penile shaft. Skin lesions are also 
common in BD.3 
Oral aphthae are present in almost all patients with 
Behçet’s, and the differential diagnosis of recurrent oral 
ulcers includes herpes simplex, benign aphthous ulcers, 
infl ammatory bowel disease, Stevens-Johnson syndrome, 
and other systemic rheumatic diseases such as systemic lupus 
erythematosus. Herpes can be ruled out with culture or Tzanck 
preparation. Dental prosthetics and oral hygiene products 
can cause oral irritation and ulceration. Medications such 
as methotrexate can cause oral ulcers. Other causes of oral 
ulcers or stomatitis include pemphigoid, pemphigus vulgaris, 
cicatricial pemphigoid, lichen planus, and linear IgA disease.5
Many other disorders may be associated with the presence 
of small vessel cutaneous vasculitis, infl ammatory eye disease, 
neurologic disease, vascular disease, arthritis, or unexplained 
systemic illness. These include systemic lupus erythematosus, 
infl ammatory bowel disease, sarcoidosis, reactive arthritis, 
psoriatic arthritis, ankylosing spondylitis, juvenile arthritis, 
familial Mediterranean fever and other periodic febrile 
syndromes, other vasculitides, multiple sclerosis, systemic 
infections such as tuberculosis, human immunodefi ciency 
virus, syphilis, and malignancies.5 Based on history, physical 
examination, and laboratory investigations of serum antibody 
for some viruses, we can rule out the other differential diagnosis 
and conclude that this patient have the manifestations of BD. 
The International Study Group criteria for the diagnosis of BD 
are shown in table 1.
Table 1   International Study Group criteria for Behçet’s disease3  
Recurrent oral 
ulceration
Minor aphthous, major aphthous, or herpetiform 
ulceration observed by physician or patient, which 




Aphthous ulceration or scarring, ulceration 
observed by physician or patient
Eye lesions Anterior uveitis, posterior uveitis, or cells in 
vitreous on slit lamp examination; or retinal 
vasculitis observed by ophthalmologist
Skin lesions Erythema nodosum observed by physician or 
patient, pseudofolliculitis, or papulopustular 
lesions; or acneiform nodules observed by 
physician in postadolescent patients not receiving 
corticosteroid treatment
Positive pathergy test Read by physician at 24 to 48 hours
Cutaneous lesions occur in over 75 percent of patients with 
BD. The skin manifestations vary and may include acneiform 
lesions, papulo-vesiculo-pustular eruptions, nodules, erythema 
nodosum (septal panniculitis), superfi cial thrombophlebitis, 
pyoderma gangrenosum-type lesions, erythema multiforme-
like lesions, and palpable purpura. Biopsy of erythema 
nodosum lesions reveal a septal panniculitis, with medium 
vessel vasculitis in up to half of lesions.6 The skin lesion of this 
patient were acneiform. Unfortunately, we did not performed 
skin biopsy because this patient have already received steroid 
treatment.
Acneiform lesions may be more common in those with 
associated arthritis.7,8 This is comparable with the symptoms 
of arthralgia of this patient which came at the same time as 
skin lesion. An intermittent, symmetric oligoarthritis of the 
knees, ankles, hands, or wrists affects one half of the patients 
with BD; arthralgia is also common. An erosive or destructive 
arthropathy is unusual. Infl ammatory cells of the synovium and 
synovial fl uid are primarily polymorphonuclear leukocytes.3
Ocular disease occurs in 25 to 75 percent of BD patients. 
Ocular infl ammation typically follows mucocutaneous 
symptoms by a few years, but it often progresses with a chronic, 
relapsing course affecting both eyes. This manifestation may 
require systemic immunosuppressive treatment and may 
irreversibly impair vision, and even progress to blindness if 
left untreated.3
Overall, the clinical manifestations of this patient were 
characterized for BD. The symptom of recurrent oral ulcers 
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came fi rst followed by genital ulcer and skin lesion with 
arthralgia. Panuveitis was confi rmed after few years of fi rst 
manifestation. 
The positivity of antibody for HSV II and CMV was 
related to the pathogenesis of BD. Studies suggest a possible 
pathogenic role of certain bacterial antigens that have cross-
reactivity with human peptides. The cross-reactive self-
antigens may include the heat shock proteins, a family of 60 to 
90 kDa proteins produced by many cells in response to stress. 
These proteins have signifi cant sequence homology between 
human and bacteria. T cells and/or antibodies may recognize 
epitopes shared by both host and infectious organism heat 
shock proteins, thereby initiating and/or perpetuating Behçet’s 
disease.3,9.10
European League Against Rheumatism (EULAR) 
recommendations for the management of BD stated that 
any patient with BD and infl ammatory eye disease affecting 
the posterior segment should be on a treatment regime that 
includes azathioprine and systemic corticosteroids.11
Eye involvement in BD follows a remitting and relapsing 
course and the recurrent infl ammatory attacks result in 
irreversible damage and visual loss. Suppression of the 
infl ammation and the prevention of recurrences of ocular 
attacks should be the goals. Azathioprine is widely accepted 
as the initial agent for ocular involvement of BD.11
Placebo-controlled randomized controlled trial (RCT) 
showed that azathioprine 2.5 mg/kg/day decreased hypopyon 
uveitis attacks (number needed to treat (NNT) = 4), stabilized 
visual acuity, and decreased the development of new eye 
disease (NNT = 2). Moreover, the 7-year follow-up of these 
patients showed that the benefi cial effect of azathioprine 
continued in the long-term. Local and systemic corticosteroids 
for eye involvement, especially during attacks, are generally 
used with no evidence from RCTs. Corticosteroids rapidly 
suppress the infl ammation but potential side effects, including 
cataracts and glaucoma, can cause concern.11
From the review of 880 Turkish patients with Behçet’s 
uveitis, 68 percent were male, mean age of onset was 28.5 
years for men and 30 for women. Ocular disease was bilateral 
in 78.1 percent, and panuveitis was the most common fi nding. 
Risk of losing useful vision at 10 years was 30 percent for men 
and 17 percent for women, but prognosis was better in the 
1990s than in the 1980s.12 Surprisingly, this patient showed 
remarkable improvement after we added azathioprine 50 mg 
to 150 mg a day. Hopefully, the visual loss in this patient will 
reverse to normal. However, it is important to remember that 
BD typically has a waxing and waning course characterized 
by exacerbations and remissions. 
CONCLUSION 
Behçet’s disease is a chronic, relapsing, infl ammatory disease 
characterized by recurrent oral aphthous ulcers and numerous 
potential systemic manifestations. These include genital ulcers, 
ocular disease, skin lesions, neurologic disease, vascular 
disease, and arthritis. The disease is believed to be caused by 
vasculitis. The disease is characterized by exacerbations and a 
relapsing/remitting course. 
Azathioprine revealed good improvement in ocular 
involvement of BD and this immunosupressant is recommended 
by EULAR. However, frequent ophthalmologic examinations 
are essential for patients with ocular disease, and periodic 
monitoring of the eyes is recommended for all patients. A 
careful history and examination, with attention to the vascular 
and neurologic systems, should be part of the physician’s 
assessment.
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